公开(公告)号：US20100151566A1

公开(公告)日：2010-06-17

申请号：US12447711

申请日：2007-10-30

申请人： Humberto Lamdan Ordás ,  Jorge Víctor Gavilondo Cowley ,  Marta Ayala Avila ,  Gertrudis Rojas Dorantes ,  Yanelys Morera Díaz ,  Osmany Guirola Cruz ,  Glay Chinea Santiago ,  Nelson Francisco Santiago Vispo

发明人： Humberto Lamdan Ordás ,  Jorge Víctor Gavilondo Cowley ,  Marta Ayala Avila ,  Gertrudis Rojas Dorantes ,  Yanelys Morera Díaz ,  Osmany Guirola Cruz ,  Glay Chinea Santiago ,  Nelson Francisco Santiago Vispo

IPC分类号： C12N15/74 ,  C07K16/18

CPC分类号： C07K16/22 ,  A61K2039/505 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2319/00

摘要： The present invention deals with recombinant polypeptide molecules related to antibodies, that specifically recognize the human Vascular Endothelial Growth Factor A (VEGF-A), and interfere with its in vitro stimulatory effects and pro-angiogenic activity in vivo. These recombinant polypeptide molecules affect proliferation of human endothelial cells in vitro, subcutaneous angiogenesis in mice induced by Matrigel pellets that contain VEGF-A and the growth of human tumors transplanted in nude athymic mice. Several of these moleculas prevent choroideal neovascularization in a non human primate experimental model. These molecules can be employed for passive immunotherapy in pathological entities which have in its base an abnormal increase in blood vessels, as: age-related macular degeneration (wet variant), cancer and its metastases, neovascular glaucoma, diabetic and newborn retinopathies, acute and chronic inflammatory processes, infectious diseases, autoimmune diseases, organ transplant rejection, hemangioma, angiofibroma, and others.

摘要翻译： 本发明涉及与抗体相关的重组多肽分子，其特异性识别人血管内皮生长因子A（VEGF-A），并且干扰其在体内的体外刺激作用和促血管生成活性。 这些重组多肽分子影响体外人体内皮细胞的增殖，小鼠皮下血管生成，由含有VEGF-A的Matrigel颗粒诱导，并且移植在裸露无胸腺小鼠中的人类肿瘤的生长。 这些分子中的几个在非人灵长类动物实验模型中阻止氯化物新生血管形成。 这些分子可用于病理实体中的被动免疫治疗，其基础是血管异常增加，如：年龄相关性黄斑变性（湿性变体），癌症及其转移，新生血管性青光眼，糖尿病和新生儿视网膜病变，急性和 慢性炎症过程，传染病，自身免疫性疾病，器官移植排斥，血管瘤，血管纤维瘤等。